Galvani Biolectronics is a Verily/GSK company, created to accelerate the research, development and commercialization of bioelectronic medicines. The goal is to find solutions to manage chronic diseases, such as arthritis, diabetes, and asthma, using miniaturized electronics. Implanted devices would modify electrical signals that pass along nerves, including irregular impulses that occur in illness.
Initial work will focus on developing precision devices for inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where substantial evidence already exists in animal models.
Every major pharmaceutical company (globally) attended ApplySci’s recent Wearable Tech + Digital Health + NeuroTech conferences in San Francisco and New York. We believe that partnerships similar to the Verily/GSK venture will proliferate — and that they will improve the lives of those with chronic diseases.
Digital Health + NeuroTech Silicon Valley – February 7-8, 2017 @ Stanford University